KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Pacific Biosciences Of California (PACB) over the last 17 years, with Q3 2025 value amounting to -$18.7 million.

  • Pacific Biosciences Of California's Cash from Operations rose 5885.23% to -$18.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.8 million, marking a year-over-year increase of 4729.32%. This contributed to the annual value of -$206.1 million for FY2024, which is 2049.4% up from last year.
  • Latest data reveals that Pacific Biosciences Of California reported Cash from Operations of -$18.7 million as of Q3 2025, which was up 5885.23% from -$29.4 million recorded in Q2 2025.
  • Over the past 5 years, Pacific Biosciences Of California's Cash from Operations peaked at -$15.7 million during Q2 2021, and registered a low of -$94.7 million during Q1 2023.
  • For the 5-year period, Pacific Biosciences Of California's Cash from Operations averaged around -$49.0 million, with its median value being -$45.5 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 28545.7% in 2022, then surged by 5885.23% in 2025.
  • Quarter analysis of 5 years shows Pacific Biosciences Of California's Cash from Operations stood at -$31.7 million in 2021, then crashed by 91.01% to -$60.6 million in 2022, then grew by 4.96% to -$57.6 million in 2023, then soared by 46.75% to -$30.6 million in 2024, then surged by 38.97% to -$18.7 million in 2025.
  • Its Cash from Operations stands at -$18.7 million for Q3 2025, versus -$29.4 million for Q2 2025 and -$44.1 million for Q1 2025.